Homepage > Company > Media > Pharma News > 2022 > Merck KGaA to Pay Over $3 Million to Patients After Thyroid Drug Formulation Change

Merck KGaA to Pay Over $3 Million to Patients After Thyroid Drug Formulation Change

France’s highest court has ordered European drugmaker Merck KGaA to pay more than $3.6 million to patients who received a thyroid drug Levothyrox (levothyroxine sodium) with diminished quality following a change in its formulation.

In 2017, the company removed lactose and added mannitol and citric acid to the drug’s formulation to make it easier to tolerate.

But patients complained of diminished efficacy and side effects, which included dizziness, headaches, memory loss, extreme fatigue, hair loss, digestive problems, muscle cramps, depression — and even thyroid cancer.

Per the ruling, the company will pay each of the 3,330 plaintiffs more than $1,100 in damages.

March 21, 2022

https://www.fdanews.com/

Read also

UK and US agree on landmark pharma pricing tariff deal

The UK and US have agreed to keep tariffs on UK pharmaceutical shipments into the US at zero.

Parkinson's drug as basis for new anti-infectives

Pseudomonas aeruginosa – one of the most common hospital germs – has sophisticated mechanisms to efficiently infect the human body and evade the immune system or antibiotics.

Modified herpes virus helps destroy glioblastoma in preclinical models

Researchers at Mass General Brigham have modified a herpes simplex virus (HSV-1) that stimulates the immune system to attack glioblastoma cells.

Curi Bio: $10 Million Series B Closed To Scale Human-Relevant Preclinical Platforms

Curi Bio has secured a $10 million Series B round led by Seoul-based contract research organization DreamCIS, funding that will accelerate the expansion of the company’s integrated human-relevant pr...